Originally posted on 1/31/2013
A New York Times
article this week talks about the efforts of drug companies and biotechs to capitalize on the growing market for "orphan" diseases, rare diseases for which drugs on the market can cost upwards of $300,000. The piece discusses this issue through the story of a partnership between NPS Pharmaceutical and the Short Bowel Syndrome Foundation
We at ASAP Media have talked a great deal about alliances for social good and public-private partnerships, but even we tend to gloss over partnerships like this that fall in between. The fact is that nonprofits have been major facilitators of many powerful alliances, with or without the additional participation of a public entity. And as the alliance management community is quick to tell you, nonprofit involvement can still drive a partnership initiative to greater profits. The objectives of these profits aren't always confined specifically to bolstering the public good.